Search results
Results From The WOW.Com Content Network
domperidone 10 mg fast-melting tablets Portugal: Medinfar: Cinet: domperidone 1 mg/ml oral suspension (200 ml) Russia: Janssen Pharmaceutica: Motilium: domperidone 10 mg film-coated tablets & ODT; 1 mg/ml suspension (100 ml) -OBL Pharm: Passagix: domperidone 10 mg film-coated tablets & chewable tablets -Dr. Reddy's Laboratories: Omez D
An antiemetic is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, and chemotherapy directed against cancer. They may be used for severe cases of gastroenteritis, especially if the patient is dehydrated. [1] [2]
The most common side effects of tramadol in order of decreasing incidence are: [1] [2 ... Serious adverse effects are in bold. Very common (>10% frequency) ...
From or to a drug trade name: This is a redirect from (or to) the trade name of a drug to (or from) the international nonproprietary name (INN).
A blister package of Ganaton (Itopride) 50 mg tablets intended for distribution in the Slovak Republic. Typically, itopride is indicated in the treatment of GI symptoms caused by reduced GI motility: dyspepsia of a non-ulcer/dysmotility type (gastric "fullness", discomfort, and possible pain) [7] [8] gastroparesis (delayed gastric emptying) [9 ...
Motilin is a 22-amino acid polypeptide hormone in the motilin family that, in humans, is encoded by the MLN gene. [2]Motilin is secreted by endocrine Mo cells [3] [4] (also referred to as M cells, which are not the same as the M cells, or microfold cells, found in Peyer's patches) that are numerous in crypts of the small intestine, especially in the duodenum and jejunum. [5]
These side effects may occur in as many as 90% of men treated with bicalutamide monotherapy, [29] but gynecomastia is generally reported to occur in 70 to 80% of patients. [30] In the EPC trial, at a median follow-up of 7.4 years, breast pain and gynecomastia respectively occurred in 73.6% and 68.8% of men treated with 150 mg/day bicalutamide ...
There were no obvious differences in effectiveness of raloxifene in the MORE trial for prevention of breast cancer at a dosage of 60 mg/m 2 /day relative to 120 mg/m 2 /day. [14] In the Study of Tamoxifen and Raloxifene (STAR) trial, 60 mg/day raloxifene was 78% as effective as 20 mg/day tamoxifen in preventing non-invasive breast cancer. [ 15 ]